Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€1.64

€1.64

-1.780%
-0.03
-1.780%
-
 
13.06.25 / Tradegate WKN: A2QJV6 / Name: Vivoryon Therapeutics / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:

Vivoryon Therapeutics N.V. Stock

We can see a decrease in the price for Vivoryon Therapeutics N.V.. Compared to yesterday it has lost -€0.030 (-1.780%).
For the coming years our community has positive and negative things to say abot the Vivoryon Therapeutics N.V. stock. Criterium "Company culture" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Vivoryon Therapeutics N.V. in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Vivoryon Therapeutics N.V. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Vivoryon Therapeutics N.V. -1.780% -2.962% -5.645% -24.862% -18.018% -80.407% -57.946%
Heidelberg Pharma AG -9.470% -10.204% 35.385% 54.386% 85.654% -7.950% -3.930%
Nanorepro AG 0.610% 0.613% 22.846% -6.017% 23.774% -51.765% 2.500%
Larimar Therapeutics Inc. -3.170% 15.094% 46.988% -72.273% -34.409% 14.019% -81.402%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

Analyzing the financials of Vivoryon Therapeutics (US Symbol: VIV) reveals a company navigating through significant challenges in the Biotechnology & Medical Research sector. While the company presents an intriguing profile in terms of its potential, a closer examination of the financial ratios, balance sheets, and cash flow statements paints a picture that is both nuanced and cautionary.

The financial landscape of Vivoryon Therapeutics reflects a company that is still in its developmental phase, struggling to achieve profitability while engaging in promising research and potential product development. Key metrics show that while there are positive aspects to consider, such as gross profits, the overall performance indicators raise concerns about the sustainability of its business model and its ability to attract future investment.

Gross Profit: One of the brighter spots in the financial statements is the gross profit of about $9.2 million. This indicates that when the company generates revenue, it retains a significant portion as gross profit, displaying the potential for operational effectiveness once revenue generation increases.